Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : U.S. FDA set to authorize Pfizer COVID-19 shot for ages 12-15 early next week - NYT

05/03/2021 | 05:36pm EDT

May 3 (Reuters) - The U.S. Food and Drug Administration is preparing to authorize Pfizer Inc and German partner BioNTech SE's COVID-19 vaccine for adolescents aged between 12 and 15 years by early next week, the New York Times reported on Monday, citing federal officials familiar with the agency's plans.

An approval is highly anticipated after the drugmakers said in March that the vaccine was found to be safe, effective and produced robust antibody responses in 12- to 15-year-olds in a clinical trial.

Responding to a Reuters request for comment, the FDA said its review of expanding the vaccine's emergency use authorization is ongoing, but did not provide further details.

The vaccine has already been cleared in the United States for people aged 16 and above. (https://reut.rs/3nLH8Fj)

Pfizer declined to comment on the NYT report.

The U.S. Centers for Disease Control (CDC) Director Rochelle Walensky said earlier in April that the vaccine could be approved by mid-May.

If an approval for the 12-15 year olds is granted, the CDC's vaccine advisory panel will likely meet the following day to review the clinical trial data and make recommendations for the vaccine's use in adolescents, the report added. (https://nyti.ms/3eclRld)

A potential approval of the vaccine would boost the country's immunization drive and help allay fears of parents anxious to protect their children from COVID-19.

Moderna Inc and Johnson & Johnson are also testing their vaccines in 12- to 18-year olds, with data from Moderna's trial expected to come soon.

Pfizer and Moderna have also launched trials in even younger children, aged six months to 11 years old. Both companies have said they hope to be able to vaccinate children under 11 as soon as early 2022.

(Reporting by Trisha Roy in Bengaluru; Editing by Devika Syamnath)


© Reuters 2021
All news about MODERNA, INC.
03:16pMODERNA  : All adults can book COVID vax at select Ontario hot spot pharmacies
AQ
02:15pMODERNA  : U.S. CDC Says Delivered 329,840,055 Doses Of Covid-19 Vaccine As Of M..
RE
02:11pMODERNA  : U.S. administers 257.3 mln doses of COVID-19 vaccines –CDC
RE
04:01aWho have provinces pegged to receive COVID-19 vaccines in the coming weeks?
AQ
05/07Correction to Impact of U.S. Support for Patent Waiver on Vaccine Makers Arti..
DJ
05/07BILL GATES : Stocks That Defined the Week
DJ
05/07ASTRAZENECA PHARMA INDIA  : Key EU countries rebuff Biden on sharing COVID vacci..
RE
05/07AstraZeneca Weighs Seeking Full U.S. Approval for Covid Shot, Skipping Emerge..
DJ
05/07AstraZeneca Weighs Seeking Full U.S. Approval for Covid Shot, Skipping Emerge..
DJ
05/07MARKET CHATTER : WHO's Director General Calls for Countries to Support Waiving C..
MT
More news
Financials (USD)
Sales 2021 18 212 M - -
Net income 2021 10 334 M - -
Net cash 2021 12 094 M - -
P/E ratio 2021 6,58x
Yield 2021 -
Capitalization 65 346 M 65 346 M -
EV / Sales 2021 2,92x
EV / Sales 2022 2,90x
Nbr of Employees 1 300
Free-Float 88,7%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 166,20 $
Last Close Price 163,15 $
Spread / Highest target 41,6%
Spread / Average Target 1,87%
Spread / Lowest Target -49,1%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.56.17%65 346
LONZA GROUP AG1.51%47 533
IQVIA HOLDINGS INC.30.82%44 923
CELLTRION, INC.-25.77%32 687
SEAGEN INC.-20.36%25 314
CUREVAC N.V.23.84%21 497